TY - JOUR
T1 - Atopic Dermatitis and Food Allergy
T2 - Best Practices and Knowledge Gaps—A Work Group Report from the AAAAI Allergic Skin Diseases Committee and Leadership Institute Project
AU - Singh, Anne Marie
AU - Anvari, Sara
AU - Hauk, Pia
AU - Lio, Peter
AU - Nanda, Anil
AU - Sidbury, Robert
AU - Schneider, Lynda
N1 - Funding Information:
No funding was received for this work. Conflicts of interest: A. M. Singh receives research funding from the National Institutes of Health (NIH), has received consulting fees from Abbvie, and serves on a DSMB for Siolta Therapeutics. S. Anvari receives research funding from NIH and clinical trial funding from DBV and NIH. P. Lio has grant funding from AOBiome, Regenerone/Sanoif Genzyme, and Abbvie; royalties or licenses from Theraplex AIM (OTC); consulting fees from Almirall, ASLAN, Dermavant, Regenerone/Sanofi, Pfizer, LEO, Abbvie, Lilly, Micreos, L'Oreal, Pierre-Fabre, J&J, Level Ex, KPAway, Unilever, Menlo, Theraplex, IntraDerm, AoBiome, Galderma, Altus, Verrica, Arbonne, Amyris, My-Or, and Kimberly Clark; speakers fees from Regeneron/Sanofi, Pfizer, Eli Lilly, LEO, Galderma, and L'Oreal; support for travel from Regeeneron, Pfizer, Eli Lilly, LEO, Galderma, and L'Oreal; patents planned, issued, or pending from Theraplex AIM (OTC); is a board member of the National Eczema Association; and has stock options with Miceos, YoBee Care, Altus, KPAway, and LearnSkin. R. Sidbury received research funds from Regeneron, Pfizer, Galderma, and UCB; he is on a steering committee for Arcaida trials but received no compensation for this. L. Schneider has received payment for clinical trials from Regeneron, DBV Technologies, Genetech, and Pfizer; serves on a DSMB or advisory board to Alladapt Immunotherapeutics, Biothea Therapeutics, National Institutes of Allergy and Infectious Diseases, and DBV Technologies; serves on the FARE Medical Advisory Board; and has possible stock for serving on the Scientific Advisory Board to Ukko. The rest of the authors declare that they have no relevant conflicts of interest. This work group report was completed as a part of the AAAAI Leadership Institute (A. M. Singh).
Funding Information:
Conflicts of interest: A. M. Singh receives research funding from the National Institutes of Health (NIH), has received consulting fees from Abbvie, and serves on a DSMB for Siolta Therapeutics. S. Anvari receives research funding from NIH and clinical trial funding from DBV and NIH. P. Lio has grant funding from AOBiome, Regenerone/Sanoif Genzyme, and Abbvie; royalties or licenses from Theraplex AIM (OTC); consulting fees from Almirall, ASLAN, Dermavant, Regenerone/Sanofi, Pfizer, LEO, Abbvie, Lilly, Micreos, L’Oreal, Pierre-Fabre, J&J, Level Ex, KPAway, Unilever, Menlo, Theraplex, IntraDerm, AoBiome, Galderma, Altus, Verrica, Arbonne, Amyris, My-Or, and Kimberly Clark; speakers fees from Regeneron/Sanofi, Pfizer, Eli Lilly, LEO, Galderma, and L’Oreal; support for travel from Regeeneron, Pfizer, Eli Lilly, LEO, Galderma, and L’Oreal; patents planned, issued, or pending from Theraplex AIM (OTC); is a board member of the National Eczema Association; and has stock options with Miceos, YoBee Care, Altus, KPAway, and LearnSkin. R. Sidbury received research funds from Regeneron, Pfizer, Galderma, and UCB; he is on a steering committee for Arcaida trials but received no compensation for this. L. Schneider has received payment for clinical trials from Regeneron, DBV Technologies, Genetech, and Pfizer; serves on a DSMB or advisory board to Alladapt Immunotherapeutics, Biothea Therapeutics, National Institutes of Allergy and Infectious Diseases, and DBV Technologies; serves on the FARE Medical Advisory Board; and has possible stock for serving on the Scientific Advisory Board to Ukko. The rest of the authors declare that they have no relevant conflicts of interest. This work group report was completed as a part of the AAAAI Leadership Institute (A. M. Singh).
Publisher Copyright:
© 2022 American Academy of Allergy, Asthma & Immunology
PY - 2022/3
Y1 - 2022/3
N2 - Allergists are often asked to evaluate children with atopic dermatitis (AD) for allergen triggers to disease. Testing, particularly for food triggers, often leads to elimination diets in an effort to improve AD control. However, the dual exposure hypothesis suggests that oral tolerance to food antigens is promoted through high-dose oral exposure, where sensitization occurs through lower dose cutaneous exposure. This suggests that strict elimination diets may pose some risks in children with AD. In addition, emerging evidence suggests an important role of skin inflammation in further allergic disease and the importance of dietary exposure to maintain oral tolerance. This work group report reviews current guidelines-based management for children with moderate-to-severe AD, the evidence for current recommendations for the evaluation and management of these children, provides a nuanced examination of these studies, and addresses current knowledge gaps in the care of these children.
AB - Allergists are often asked to evaluate children with atopic dermatitis (AD) for allergen triggers to disease. Testing, particularly for food triggers, often leads to elimination diets in an effort to improve AD control. However, the dual exposure hypothesis suggests that oral tolerance to food antigens is promoted through high-dose oral exposure, where sensitization occurs through lower dose cutaneous exposure. This suggests that strict elimination diets may pose some risks in children with AD. In addition, emerging evidence suggests an important role of skin inflammation in further allergic disease and the importance of dietary exposure to maintain oral tolerance. This work group report reviews current guidelines-based management for children with moderate-to-severe AD, the evidence for current recommendations for the evaluation and management of these children, provides a nuanced examination of these studies, and addresses current knowledge gaps in the care of these children.
KW - Atopic dermatitis
KW - Food allergy
KW - Skin care
UR - http://www.scopus.com/inward/record.url?scp=85123739820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123739820&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.12.037
DO - 10.1016/j.jaip.2021.12.037
M3 - Article
C2 - 35101439
AN - SCOPUS:85123739820
SN - 2213-2198
VL - 10
SP - 697
EP - 706
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 3
ER -